Login to Your Account

Humira Approval, Litigation End Spell Fresh Start To CAT's Year

By Nuala Moran

Wednesday, January 8, 2003
LONDON - Cambridge Antibody Technology plc had a cheery start to the New Year with news that partner Abbott Laboratories Inc. received FDA approval earlier than anticipated to market Humira for rheumatoid arthritis, and the drug will begin shipping this month. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription